Xavier Castellsagué

Xavier Castellsagué

Auto-generated profile, based on publicly available information

Xavier Castellsagué

Institut Catala d’Oncologia, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2003 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
NMNubia Muñoz
Nubia Muñoz
FBF Xavier Bosch
F Xavier Bosch
SSSilvia De Sanjosé
Silvia De Sanjosé
RHRolando Herrero
Rolando Herrero
XCXavier Castellsagué
Xavier Castellsagué
IGInternational Agency for Research on Cancer Multicenter Cervical Cancer Study Group
International Agency for Research on Cancer Multicenter Cervical Cancer Study Group
Infection with human papilloma virus (HPV) is the main cause of cervical cancer, but the risk associated with the various HPV types has not been adequately assessed. We pooled data from 11 case–control studies from nine countries involving 1918 women with histologically confirmed squamous-cell cervical cancer and 1928 control women. A common protocol and questionnaire were used. Information on risk factors was obtained by personal interviews, and cervical cells were collected for detection of HPV DNA and typing in a central laboratory by polymerase-chain-reaction–based assays (with MY09/MY11 and GP5+/6+ primers). HPV DNA was detected in 1739 of the 1918 patients with cervical cancer (90.7 percent) and in 259 of the 1928 control women (13.4 percent). With the GP5+/6+ primer, HPV DNA was detected in 96.6 percent of the patients and 15.6 percent of the controls. The most common HPV types in patients, in descending order of frequency, were types 16, 18, 45, 31, 33, 52, 58, and 35. Among control women, types 16, 18, 45, 31, 6, 58, 35, and 33 were the most common. For studies using the GP5+/6+ primer, the pooled odds ratio for cervical cancer associated with the presence of any HPV was 158.2 (95 percent confidence interval, 113.4 to 220.6). The odds ratios were over 45 for the most common and least common HPV types. Fifteen HPV types were classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 3 were classified as probable high-risk types (26, 53, and 66); and 12 were classified as low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108). There was good agreement between our epidemiologic classification and the classification based on phylogenetic grouping. In addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 should be considered carcinogenic, or high-risk, types, and types 26, 53, and 66 should be considered probably carcinogenic.

1 November 2010 in The Lancet Oncology
Verified
Journal Article
Closed access
SSSilvia De Sanjosé
Silvia De Sanjosé
WQWim Gv Quint
Wim Gv Quint
LALaia Alemany
Laia Alemany
DGDaan T Geraets
Daan T Geraets
JKJo Ellen Klaustermeier
Jo Ellen Klaustermeier
FBF Xavier Bosch
F Xavier Bosch

15 December 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
LBLaia Bruni
Laia Bruni
MDMireia Diaz
Mireia Diaz
XCXavier Castellsagué
Xavier Castellsagué
EFElena Ferrer
Elena Ferrer
FBF. Xavier Bosch
F. Xavier Bosch
SSSilvia de Sanjosé
Silvia de Sanjosé
Baseline information on human papillomavirus (HPV) prevalence and type distribution is highly desirable to evaluate the impact of prophylactic HPV vaccines in the near future. A meta-analysis was performed of studies published between 1995 and 2009 that used polymerase chain reaction or Hybrid Capture 2 for HPV detection in women with normal cytological findings. The analysis included 194 studies comprising 1,016,719 women with normal cytological findings. The estimated global HPV prevalence was 11.7% (95% confidence interval, 11.6%-11.7%). Sub-Saharan Africa (24.0%), Eastern Europe (21.4%), and Latin America (16.1%) showed the highest prevalences. Age-specific HPV distribution presented with a first peak at younger ages (<25 years) and, in the Americas and Africa, a rebound at older ages (≥45 years). Among the women with type-specific HPV data (n = 215,568), the 5 most common types worldwide were HPV-16 (3.2%), HPV-18 (1.4%), HPV-52 (0.9%), HPV-31 (0.8%), and HPV-58 (0.7%). Although the prevalence of HPV in women with normal cytological findings is high and variable across world regions, HPV types 16, 18, 31, 52, and 58 are consistently found among the 10 most common types in all of them. These results represent the most comprehensive assessment of HPV burden among women with normal cytological findings in the pre-HPV vaccination era worldwide.

1 July 2009 in The Lancet
Verified
Journal Article
Closed access
JPJorma Paavonen
Jorma Paavonen
PNP Naud
P Naud
JSJorge Salmerón
Jorge Salmerón
CWC M Wheeler
C M Wheeler
SCS-N Chow
S-N Chow
HGHPV PATRICIA Study Group
HPV PATRICIA Study Group

1 July 2007 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
SSSilvia De Sanjosé
Silvia De Sanjosé
MDMireia Diaz
Mireia Diaz
XCXavier Castellsagué
Xavier Castellsagué
GCGary Clifford
Gary Clifford
LBLaia Bruni
Laia Bruni
FBF Xavier Bosch
F Xavier Bosch

1 February 2009 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
MHMia Hashibe
Mia Hashibe
PBPaul Brennan
Paul Brennan
SCShu-Chun Chuang
Shu-Chun Chuang
SBStefania Boccia
Stefania Boccia
XCXavier Castellsague
Xavier Castellsague
PBPaolo Boffetta
Paolo Boffetta
Background: The magnitude of risk conferred by the interaction between tobacco and alcohol use on the risk of head and neck cancers is not clear because studies have used various methods to quantify the excess head and neck cancer burden. Methods: We analyzed individual-level pooled data from 17 European and American case-control studies (11,221 cases and 16,168 controls) participating in the International Head and Neck Cancer Epidemiology consortium. We estimated the multiplicative interaction parameter (ψ) and population attributable risks (PAR). Results: A greater than multiplicative joint effect between ever tobacco and alcohol use was observed for head and neck cancer risk (ψ = 2.15; 95% confidence interval, 1.53-3.04). The PAR for tobacco or alcohol was 72% (95% confidence interval, 61-79%) for head and neck cancer, of which 4% was due to alcohol alone, 33% was due to tobacco alone, and 35% was due to tobacco and alcohol combined. The total PAR differed by subsite (64% for oral cavity cancer, 72% for pharyngeal cancer, 89% for laryngeal cancer), by sex (74% for men, 57% for women), by age (33% for cases 60 years), and by region (84% in Europe, 51% in North America, 83% in Latin America). Conclusions: Our results confirm that the joint effect between tobacco and alcohol use is greater than multiplicative on head and neck cancer risk. However, a substantial proportion of head and neck cancers cannot be attributed to tobacco or alcohol use, particularly for oral cavity cancer and for head and neck cancer among women and among young-onset cases. (Cancer Epidemiol Biomarkers Prev 2009;18(2):541–50)